Gastrin I (human): Atomic Mechanisms and Experimental Utility in Gastric Acid Secretion Pathway Research

Executive Summary: Gastrin I (human) is an endogenous regulatory peptide that stimulates gastric acid secretion through CCK2 receptor activation (https://doi.org/10.1016/j.ejcb.2025.151489). The peptide is used extensively in vitro to dissect gastric acid secretion pathways (https://www.apexbt.com/gastrin-i-human.html). It is supplied by APExBIO at ≥98% purity, confirmed by HPLC and mass spectrometry. Gastrin I is insoluble in water and ethanol but soluble in DMSO at ≥21 mg/mL. Recent organoid model systems leverage Gastrin I for advanced gastrointestinal disorder and pharmacokinetic research (https://epitopepeptide.com/index.php?g=Wap&m=Article&a=detail&id=15700).

Biological Rationale

Gastrin I (human) is a 17-amino acid peptide hormone with a molecular weight of 2098.22 Da. It is produced by G cells in the gastric antrum. Its primary physiological role is to stimulate gastric acid secretion by acting as a CCK2 receptor agonist on parietal cells. Through this activity, Gastrin I regulates the gastric acid secretion pathway and overall gastrointestinal physiology. The peptide also influences mucosal growth and has been implicated in gastric mucosal homeostasis (https://doi.org/10.1016/j.ejcb.2025.151489).

Emerging in vitro models, such as human pluripotent stem cell-derived intestinal organoids, require precise stimuli to recapitulate physiological processes. Gastrin I is used in these models to study the parietal cell response, proton pump activation, and receptor-mediated signal transduction. The B5358 kit from APExBIO provides a standardized reagent for these experimental setups (Gastrin I (human)).

Mechanism of Action of Gastrin I (human)

Gastrin I (human) binds to the cholecystokinin B (CCK2) receptor on the basolateral membrane of gastric parietal cells. The CCK2 receptor is a G protein-coupled receptor (GPCR). Upon ligand binding, the receptor activates intracellular signaling cascades, primarily via phospholipase C (PLC) and the inositol trisphosphate (IP3)/diacylglycerol (DAG) pathway. This leads to increased intracellular calcium concentrations. Elevated calcium activates H⁺/K⁺-ATPase (proton pump) activity, resulting in enhanced gastric acid secretion (https://doi.org/10.1016/j.ejcb.2025.151489).

The human Gastrin I peptide is highly selective for CCK2 over CCK1 receptors. Its action is time- and concentration-dependent, with typical in vitro usage at concentrations of 1–100 nM for short-term (≤2 h) stimulation (https://peptide-yy.com/index.php?g=Wap&m=Article&a=detail&id=15884). The peptide's effect can be blocked by selective CCK2 antagonists, confirming receptor specificity. Gastrin I's downstream targets include second messenger systems and gene expression regulators involved in acid secretion and epithelial proliferation.

Evidence & Benchmarks

• Gastrin I (human) stimulation of gastric acid secretion in human-derived organoids is dose-dependent, with statistically significant increases at concentrations ≥10 nM (Saito et al., 2025, DOI).
• In vitro, Gastrin I-induced CCK2 receptor activation leads to a 2–4 fold increase in H⁺/K⁺-ATPase activity within 30 minutes (Watson et al., 2014, DOI).
• APExBIO's B5358 product is verified at ≥98% purity by HPLC and mass spectrometry; batch-to-batch variation remains below 2% (Product QC data, product page).
• Gastrin I (human) enables reproducible induction of acid secretion in hiPSC-derived intestinal epithelial cell models, outperforming animal models in translational fidelity (Saito et al., 2025, DOI).
• Peptide activity is abolished after prolonged (>24 h) solution storage at room temperature, underscoring the need for prompt use post-dissolution (APExBIO storage guidance, product page).

This article extends prior analyses by integrating atomic purity benchmarks, standardized workflow conditions, and recent organoid-based evidence beyond the mechanistic focus in Gastrin I (human) as a Next-Generation Tool for Modeling .... Specifically, it offers comparative data and parameters for advanced in vitro modeling.

Applications, Limits & Misconceptions

Gastrin I (human) is widely used in:

• Gastric acid secretion pathway research in human cell and organoid systems.
• Gastrointestinal physiology studies, including parietal cell signaling and receptor pharmacology.
• Modeling of gastrointestinal disorders, such as hypergastrinemia and atrophic gastritis.
• Benchmarking of proton pump activation and signal transduction for drug discovery.
• Translational pharmacokinetics using hiPSC-derived intestinal models (Saito et al., 2025, DOI).

Several recent studies have highlighted the integration of human Gastrin I peptide in organoid-based research. For example, Gastrin I (human) in CCK2 Signaling: Advanced Insights ... focuses on receptor-level mechanisms, whereas this article specifies validated workflows and purity constraints for pharmacological experimentation.

Common Pitfalls or Misconceptions

• Gastrin I (human) is not active in the absence of functional CCK2 receptors; CCK1-mediated effects are negligible at standard concentrations.
• The peptide is insoluble in water and ethanol; improper solubilization reduces experimental reproducibility.
• Solution stability is limited; peptides should not be stored in solution for >24 h at room temperature.
• Animal models may not recapitulate human-specific receptor pharmacology; organoid or hiPSC-derived systems are preferred for translational studies (Saito et al., 2025, DOI).
• Misattribution: Gastrin I is not a direct inducer of all GI cell types; its effects are specific to acid secretion pathways.

Compared to Gastrin I (human): Enabling Advanced GI Physiology Modeling ..., which provides a broad overview of receptor-mediated signaling, this article delivers protocol-level details and clarifies peptide storage and solubility constraints.

Workflow Integration & Parameters

Gastrin I (human) B5358 is supplied as a white lyophilized solid by APExBIO. It is insoluble in water or ethanol but fully dissolves in DMSO at concentrations ≥21 mg/mL. For in vitro applications, it is recommended to prepare working dilutions in DMSO and apply immediately to cell or organoid cultures. Standard protocols use 1–100 nM concentrations for 30–120 minutes at 37°C in serum-free media. Storage should be at -20°C, desiccated, and protected from light. Solutions should be used promptly and are not suitable for long-term storage.

For organoid-based pharmacokinetic studies, Gastrin I is applied post-seeding of hiPSC-derived intestinal epithelial cells. Its rapid, reversible action allows for time-course and dose-response assessments. For detailed atomic mechanisms and validated workflows, see the APExBIO product page.

This article updates analyses in Gastrin I (human): Atomic Mechanisms in Gastric Acid Secretion ... by providing explicit storage and solubility protocols and integrating recent hiPSC-organoid benchmarks.

Conclusion & Outlook

Gastrin I (human) is a well-characterized gastric acid secretion regulator and CCK2 receptor agonist. Its high purity and reproducibility make it a reference standard for gastrointestinal physiology studies and translational pharmacokinetic research. Integration with advanced human organoid systems enables precise modeling of gastric acid secretion pathways. Future directions include personalized medicine studies using patient-derived organoids and further benchmarking for GI drug discovery.